Phase 3 Clinical Trials With Primary Completion Dates in April 2020
This is a list of Phase 3 trials with primary completion dates in April 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|CBDY||Target Group Inc.||2020-04-01||Phase 3||NCT03180307||OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer|
|CHHL||China Holdings, Inc.||2020-04-01||Phase 3||NCT02971345||Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus|
|DCTH||Delcath Systems, Inc.||2020-04-01||Phase 3||NCT02678572||Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma|
|IMMU||Immunomedics, Inc.||2020-04-01||Phase 3||NCT02574455||ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer|
|INO||Inovio Pharmaceuticals, Inc.||2020-04-01||Phase 3||NCT03185013||REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)|
|NERV||Minerva Neurosciences, Inc.||2020-04-01||Phase 3||NCT03397134||Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia|
|OPHLY||Ono Pharmaceutical Co., Ltd.||2020-04-01||Phase 3||NCT03117049||Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)|